The FDA has approved the marketing of tamoxifen oral solution (Soltamox™, Savient) for the treatment and prevention of breast cancer. This is the first liquid form of drug tamoxifen to be available in the U.S.
This product has caused uterine cancer, strokes, and blood clots, but the benefits may outweigh the risks in women who already have breast cancer. It should not be used in women who need a coumarin-type anticoagulant. Cataracts may also be more common with the use of this drug. Adverse reactions include hot flashes and vaginal discharge.